AI Summary & Key Takeaways
AI InsightA statistical comparison of these acylcarnitines between subjects and controls showed a statistically significant effect (p
📌 3 Key Takeaways
Abstract
Purpose: To evaluate whether valproic acid (VPA) treatment in children with epilepsy affects the plasma fatty acylcarnitine esters. Materials and Methods: Fifty children (mean age, 10±3.9) with epilepsy receiving VPA treatment for at least one year were evaluated along with 110 children of similar age as a control group. Levels of free carnitine and acylcarnitine profiles were studied with tandem mass spectrometry (Tan-dem-MS). Results: Free camitine levels were within the normal limits. Valproic acid was found to affect the levels of the following individual acylcarnitines (medians): C4-acylcarnitine (0.56 umol/L; controls 0.39 umol/L), 3-hyd-roxy-isovalerylcamitine (C5-OH) (0.23 umol/L; controls 0.14 umol/L), C14-acylcarnitine (0.11 umol/L; controls 0.16 umol/L), C16-acylcarnitine (0.76 umol/L; controls 2.5 umol/L), C16-OH-acylcarnitine (0.04 umol/L; controls 0.07umol/L), and Cl8:1-acylcarnitine (0.8 umol/L; controls 0.97 umol/L). A statistical comparison of these acylcarnitines between subjects and controls showed a statistically significant effect (p
Özet
Amaç: Valproik asit (VPA) tedavisi alan epilepsili çocuklarda plazma açil-karnitin düzeylerinin etkilenip etkilenmeyeceğini araştırmak amaçlı yapılmıştır. Materyals ve Metods: En az bir yıldır VPA tedavisi alan 50 epilepsili çocuk (ortalama yaş, 10±3.9) ve benzer yaştaki 110 çocuk control grubu olarak incelenmiştir. Serbest karnitin ve açilkarnitin düzeyleri Tandem Mass Spectrometry (Tandem-MS) yöntemi kullanılarak ölçülmüştür. Sonuçlar: Serbest karnitin düzeyleri normal olarak saptanmıştır. Valproik asitin aşağıda belirtilen açilkarnitin düzeylerini kontrol grubu ile karşılaştırıldığında istatistiksel olarak anlamlı bir şekilde etkilediği (p